Metastatic melanoma: chemotherapy.

The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of 47,700 new cases diagnosed in 2000 in the United States. In the early phase of its natural history, melanoma is cured in most cases by surgery, but once the metastatic phase develops, it is almost always fatal. The treatment of metastatic melanoma remains unsatisfactory. Systemic therapy has not been successful up to now, with very low response rates to single-agent chemotherapy. Polychemotherapy has increased the response rate (RR), without a significant improvement in overall survival. Immunotherapy alone is able to induce only a few durable complete responses (CRs). New chemotherapeutic and biologic agents are now available and promising combined approaches targeting the tumor by several different mechanisms are desirable and will probably represent the future modality of treatment.

[1]  R. Parker,et al.  A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Lee,et al.  Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  O. Nanni,et al.  Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. F. Aguero,et al.  Bryostatin-1 and IL-2 Synergize to Induce IFN-γ Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy1 , 2001, The Journal of Immunology.

[5]  B. Collins,et al.  Thalidomide for malignant melanoma. , 2001, The New England journal of medicine.

[6]  D. Schadendorf,et al.  Drug‐resistance in human melanoma , 2001, International journal of cancer.

[7]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[8]  M. Pantaleo,et al.  Treatment of brain metastases of malignant melanoma with temozolomide. , 2001, The New England journal of medicine.

[9]  H. Kittler,et al.  Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients , 2001, Melanoma research.

[10]  S. Steinberg,et al.  Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Yung Future directions for temozolomide therapy. , 2001, Seminars in oncology.

[12]  D. Schwartzentruber Guidelines for the Safe Administration of High-Dose Interleukin-2 , 2001, Journal of immunotherapy.

[13]  P. Queirolo,et al.  A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma , 2001, Tumori.

[14]  M. Clay,et al.  A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma , 2001, Melanoma research.

[15]  R. Mcgarry,et al.  Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials , 2001, Melanoma research.

[16]  P. Ascierto,et al.  Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma , 2000 .

[17]  M. Bernstein,et al.  Phase II Trial of Pyrazoloacridine in Children With Solid Tumors: A Pediatric Oncology Group Phase II Study , 2000, Journal of pediatric hematology/oncology.

[18]  O. Larsson,et al.  Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway , 2000, Molecular and Cellular Endocrinology.

[19]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[20]  N. Savaraj,et al.  A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma , 2000 .

[21]  A. Eggermont,et al.  The Emerging Role of Cytokines in the Treatment of Advanced Melanoma , 2000, Oncology.

[22]  A. Eggermont,et al.  The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. , 2000, The cancer journal from Scientific American.

[23]  C. Dinney,et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  C. Begg,et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Morton,et al.  Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. V. Von Hoff,et al.  A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Rowland,et al.  Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Steinberg,et al.  Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Avril,et al.  Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. , 1999, Cancer.

[31]  J. Richards,et al.  Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Scheibenbogen,et al.  Long‐term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin‐2 in poor risk melanoma patients , 1998, Melanoma research.

[33]  S. Aamdal,et al.  Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma , 1998, Melanoma research.

[34]  M. Binder,et al.  Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. , 1998, European journal of cancer.

[35]  S. Steinberg,et al.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.

[36]  M. Atkins Immunotherapy and experimental approaches for metastatic melanoma. , 1998, Hematology/oncology clinics of North America.

[37]  B. Dréno,et al.  Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma. , 1998, European journal of dermatology : EJD.

[38]  A. Buzaid,et al.  Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Atkins,et al.  Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Barth,et al.  Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. , 1998, Cancer.

[41]  J. Grob,et al.  Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma , 1998, Melanoma research.

[42]  M. Weichenthal,et al.  Fotemustine and interferon α2b in metastatic malignant melanoma , 1998, Journal of Cancer Research and Clinical Oncology.

[43]  P. Tagliaferri,et al.  Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. , 1998, American journal of clinical oncology.

[44]  M. Del Vecchio,et al.  Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon-α in Dacarbazine-Resistant Malignant Melanoma , 1998, Tumori.

[45]  F. Fiore,et al.  Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma. , 1997, European journal of cancer.

[46]  A. Enk,et al.  Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Atkins,et al.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  M. Atkins,et al.  The treatment of metastatic melanoma with chemotherapy and biologics. , 1997, Current opinion in oncology.

[49]  A. Photiou,et al.  In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. , 1997, European journal of cancer.

[50]  J. Thompson,et al.  Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. , 1997, Seminars in oncology.

[51]  E. Maxwell,et al.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism , 1996, The Journal of experimental medicine.

[52]  M. Lotze,et al.  Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. , 1996, Journal of immunology.

[53]  B. Zee,et al.  Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  P. Quaglino,et al.  Low-dose integrated chemoimmunohormonotherapy with cisplatin, subcutaneous interleukin-2, interferon and tamoxifen for advanced metastatic melanoma—a pilot study , 1996, Melanoma research.

[55]  J. Kirkwood,et al.  Interferons in melanoma. , 1996, Current opinion in oncology.

[56]  S. Retsas,et al.  Taxol and vinorelbine: a new active combination for disseminated malignant melanoma , 1996, Anti-cancer drugs.

[57]  D. V. Von Hoff,et al.  Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  T. Petit,et al.  Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients , 1995, Melanoma research.

[59]  N. Savaraj,et al.  Phase II Trial of Piritrexim and DTIC Using an Alternating Dose Schedule in Metastatic Melanoma , 1995, American journal of clinical oncology.

[60]  A. Buzaid,et al.  Systemic treatments for advanced cutaneous melanoma. , 1995, Oncology.

[61]  M. Ernstoff,et al.  Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up , 1995, Melanoma research.

[62]  E. Bajetta,et al.  Combined Carboplatin and Cytosine Arabinoside in Metastatic Melanoma Refractory to Dacarbazine , 1995, Tumori.

[63]  M. Glabbeke,et al.  Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC‐Melanoma Cooperative Group (MCG) , 1995, Melanoma research.

[64]  S. Duensing,et al.  Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. , 1995, European journal of cancer.

[65]  N. Bleehen,et al.  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Fisher,et al.  Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[68]  P. Queirolo,et al.  Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[70]  A. Buzaid,et al.  Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. , 1993, Seminars in oncology.

[71]  S. Martino,et al.  A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma , 1993, Cancer.

[72]  A. Woodcock,et al.  Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. , 1993, British Journal of Cancer.

[73]  C. Boni,et al.  Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. , 1992, The New England journal of medicine.

[74]  J. Richards,et al.  Sequential chemoimmunotherapy in the treatment of metastatic melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  V. Devita,et al.  Biologic Therapy of Cancer , 1992 .

[76]  S. Aamdal,et al.  Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity. , 1992, European journal of cancer.

[77]  Hamblin Tj Interleukin-2 for anti-cancer therapy. , 1991 .

[78]  M. Atkins,et al.  Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  C. Falkson,et al.  Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  M. Aapro,et al.  Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  M. Collier,et al.  Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  D. Trump,et al.  A phase II study of taxol in patients with malignant melanoma , 1991, Investigational New Drugs.

[83]  M. Namer,et al.  Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases , 1990, Cancer.

[84]  E. Franco Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen) , 1990, Cancer.

[85]  S. Steinberg,et al.  Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  R. Benjamin,et al.  A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma , 1989, Cancer.

[87]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[88]  A. Foltz,et al.  Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma , 1988, Cancer.

[89]  S P Langdon,et al.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.

[90]  D. Guerry,et al.  WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  E. Casper,et al.  Phase II trial of carboplatin in advanced malignant melanoma. , 1987, Cancer treatment reports.

[92]  G. Bonadonna,et al.  Cytarabine and cisplatin in advanced malignant melanoma. , 1986, Cancer treatment reports.

[93]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[94]  S. Prete,et al.  Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. , 1984, Cancer treatment reports.

[95]  L. Baker,et al.  Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  E. Krementz,et al.  Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A) , 1984, Cancer.

[97]  J. Bitran,et al.  Tamoxifen in the treatment of malignant melanoma. , 1981, Cancer treatment reports.

[98]  A. Huang,et al.  DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma , 1980, Cancer.

[99]  J. Wood,et al.  Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine , 2004, Cancer Chemotherapy and Pharmacology.

[100]  K. Schallreuter,et al.  Positive phase II study in the treatment of advanced malignant melanoma with fotemustine , 2004, Cancer Chemotherapy and Pharmacology.

[101]  Takami Sato,et al.  Paclitaxel and tamoxifen , 2000, Cancer.

[102]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[104]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[105]  M. Del Vecchio,et al.  Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  G. Trinchieri Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.

[107]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[108]  S. Aamdal,et al.  Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma. , 1993, European journal of cancer.

[109]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[110]  M. Avril,et al.  Fotemustine plus dacarbazine for malignant melanoma. , 1992, European journal of cancer.

[111]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .